← Back to Search

Other

TCMCB07 for Cancer Cachexia

Phase 1
Waitlist Available
Led By Maria Bermudez, MD, CPI
Research Sponsored by Endevica Bio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

This trial is testing a new drug called TCMCB07 to help cancer patients who are experiencing severe weight loss and weakness due to cachexia. The drug aims to improve their appetite and energy levels, making them feel stronger and healthier.

Eligible Conditions
  • Cancer Cachexia
  • Cachexia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with abnormal vital signs
Number of people with abnormal Electrocardiograms
Number of people with abnormal laboratory test results
+2 more
Secondary study objectives
Area under the plasma concentration versus time curve (AUC)
Peak Plasma Concentration (Cmax)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TCMCB07Experimental Treatment1 Intervention
once daily subcutaneous injection
Group II: PlaceboPlacebo Group1 Intervention
once daily subcutaneous injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TCMCB07
2022
Completed Phase 1
~80

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Endevica BioLead Sponsor
Maria Bermudez, MD, CPIPrincipal InvestigatorQuotient Sciences
~23 spots leftby Nov 2025